{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:22:30Z","timestamp":1790050950418,"version":"4.0.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2025,9]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Clinical decision support tools in a large health system increased CKD screening in diabetics from 35% to 72%.<\/jats:p>\n <\/jats:list-item>\n \n Clinical decision support tools resulted in mixed results in CKD quality but was associated with increase in sodium-glucose cotransporter 2 inhibitor use.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Guidelines recommend screening for CKD in patients with diabetes with annual urinary albumin-creatinine ratio (ACR) and serum creatinine (Scr). However, screening rates were low in Kaiser Permanente Northwest, a large integrated health care system. We implemented a quality improvement project using clinical decision support (CDS) tools to increase ACR and Scr testing. We examined whether increased CKD screening resulted in improvement in CKD quality metrics, specifically angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and sodium-glucose cotransporter 2 inhibitor (SGLT2i) use.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In May 2022, we implemented CDS tools to increase ACR\/Scr testing consisting of automated laboratory ordering, best practice alerts (BPAs), and automated laboratory reminders to patients through letters, texts, and phone calls in tandem with provider education on best practice recommendations for CKD. A SGLT2i BPA targeting patients with type 2 diabetes with ACR \u2265300 mg\/g and eGFR \u226530 ml\/min was rolled out in June 2022 and expanded to include patients with eGFR \u226560 ml\/min regardless of CKD diagnosis in February 2023. Trends were reviewed monthly using statistical process control charts and changes in slope using segmented regression analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n After 3 years, ACR\/Scr testing conducted within 1 year increased from 35% to 72%. Angiotensin-converting enzyme inhibitor\/angiotensin receptor blockers use increased slightly from 74% to 76%, but nephrology comanagement for high-risk CKD patients remained unchanged at 53%. The rate of SGLT2i use steadily increased by 0.6% each month up until 6 months after introduction of the BPA, after which the rate increased to 1.7%. Among patients not comanaged with nephrology, the adjusted rate of increase was 7% higher in the BPA group compared with patients with CKD in the non-BPA group.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our study shows that the use of CDS tools improve CKD screening in patients with diabetes but with mixed results in CKD quality metrics.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0000000829","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T12:02:17Z","timestamp":1745496137000},"page":"1501-1509","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Improving CKD Screening and Care in Diabetes Using Clinical Decision Support in a Large Health Care System"],"prefix":"10.34067","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0429-1311","authenticated-orcid":false,"given":"Ken J.","family":"Park","sequence":"first","affiliation":[{"name":"Department of Nephrology, Kaiser Permanente Northwest, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2778-0794","authenticated-orcid":false,"given":"Michalah K.","family":"Tandy","sequence":"additional","affiliation":[{"name":"Department of Predictive Analytics, Kaiser Permanente Northwest, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6589-141X","authenticated-orcid":false,"given":"Shaun","family":"Flerchinger","sequence":"additional","affiliation":[{"name":"Department of Predictive Analytics, Kaiser Permanente Northwest, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8142-9988","authenticated-orcid":false,"given":"Kathryn J.","family":"Glassberg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kaiser Permanente Northwest, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, Kaiser Permanente Northwest, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Albright","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Kaiser Permanente Northwest, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"Nakashimada","sequence":"additional","affiliation":[{"name":"Department of Quality, Kaiser Permanente Northwest, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"suppl 1","key":"B1-20251006","first-page":"S151","article-title":"11. Microvascular complications and foot care: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care."},{"issue":"9","key":"B2-20251006","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2337\/dc20-2715","article-title":"Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations","volume":"44","author":"Stempniewicz","year":"2021","journal-title":"Diabetes Care."},{"issue":"4","key":"B3-20251006","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/HYPERTENSIONAHA.121.17323","article-title":"Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium","volume":"78","author":"Shin","year":"2021","journal-title":"Hypertension."},{"issue":"9","key":"B4-20251006","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2337\/dc21-0723","article-title":"Chronic kidney disease testing among at-risk adults in the U.S. remains low: real-world evidence from a national laboratory database","volume":"44","author":"Alfego","year":"2021","journal-title":"Diabetes Care."},{"issue":"7","key":"B5-20251006","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1681\/ASN.2018100971","article-title":"Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States","volume":"30","author":"Murphy","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"B6-20251006","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2337\/dc21-0529","article-title":"Prescribing trends of antidiabetes medications in patients with type 2 diabetes and diabetic kidney disease: a cohort study","volume":"44","author":"Harris","year":"2021","journal-title":"Diabetes Care."},{"issue":"12","key":"B7-20251006","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.2337\/dc22-0614","article-title":"Prescription patterns of cardiovascular- and kidney- protective therapies among patients with type 2 diabetes and chronic kidney disease","volume":"45","author":"Lamprea-Montealegre","year":"2022","journal-title":"Diabetes Care."},{"issue":"5S","key":"B8-20251006","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int."},{"issue":"12","key":"B9-20251006","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care."},{"issue":"10365","key":"B10-20251006","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet."},{"issue":"3","key":"B11-20251006","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1159\/000489913","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis","volume":"43","author":"Wang","year":"2018","journal-title":"Kidney Blood Press Res."},{"issue":"2","key":"B12-20251006","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ekir.2016.09.062","article-title":"Timely referral to outpatient nephrology care slows progression and reduces treatment costs of chronic kidney diseases","volume":"2","author":"Lonnemann","year":"2017","journal-title":"Kidney Int Rep."},{"issue":"5","key":"B13-20251006","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"B14-20251006","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1370\/afm.1196","article-title":"Impact of electronic health record clinical decision support on diabetes care: a randomized trial","volume":"9","author":"O\u2019Connor","year":"2011","journal-title":"Ann Fam Med."},{"issue":"1","key":"B15-20251006","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jamacardio.2022.4373","article-title":"Effect of nudges to clinicians, patients, or both to increase statin prescribing: a cluster randomized clinical trial","volume":"8","author":"Adusumalli","year":"2023","journal-title":"JAMA Cardiol."},{"issue":"22","key":"B16-20251006","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.jacc.2022.03.338","article-title":"Electronic alerts to improve heart failure therapy in outpatient practice: a cluster randomized trial","volume":"79","author":"Ghazi","year":"2022","journal-title":"J Am Coll Cardiol."},{"issue":"2","key":"B17-20251006","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.ajkd.2018.01.058","article-title":"Impact of a primary care CKD registry in a US public safety-net health care delivery system: a pragmatic randomized trial","volume":"72","author":"Tuot","year":"2018","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"B18-20251006","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/jamainternmed.2023.8315","article-title":"Clinical decision support for hypertension management in chronic kidney disease: a randomized clinical trial","volume":"184","author":"Samal","year":"2024","journal-title":"JAMA Intern Med."},{"issue":"7","key":"B19-20251006","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jamainternmed.2024.0708","article-title":"Electronic health record population health management for chronic kidney disease care: a cluster randomized clinical trial","volume":"184","author":"Jhamb","year":"2024","journal-title":"JAMA Intern Med."},{"issue":"3","key":"B20-20251006","doi-asserted-by":"crossref","first-page":"100777","DOI":"10.1016\/j.xkme.2023.100777","article-title":"A CKD clinical decision support system: a cluster randomized clinical trial in primary care clinics","volume":"6","author":"Sperl-Hillen","year":"2024","journal-title":"Kidney Med."},{"issue":"24","key":"B21-20251006","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"issue":"15","key":"B22-20251006","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"19","key":"B23-20251006","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med."},{"issue":"25","key":"B24-20251006","doi-asserted-by":"crossref","first-page":"699","DOI":"10.21105\/joss.00699","article-title":"qicharts2: quality improvement charts for R","volume":"3","author":"Anh\u00f8j","year":"2018","journal-title":"J Open Source Softw."},{"issue":"5","key":"B25-20251006","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2215\/CJN.11511015","article-title":"How to measure and interpret quality improvement data","volume":"11","author":"McQuillan","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"B26-20251006","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/qhc.12.6.458","article-title":"Statistical process control as a tool for research and healthcare improvement","volume":"12","author":"Benneyan","year":"2003","journal-title":"Qual Saf Health Care."},{"key":"B27-20251006","first-page":"20","article-title":"Segmented: an R package to fit regression models with broken-line relationships","volume":"8","author":"Muggeo","year":"2008","journal-title":"R News."},{"issue":"4","key":"B28-20251006","doi-asserted-by":"crossref","first-page":"100133","DOI":"10.1016\/j.focus.2023.100133","article-title":"Albuminuria screening in people with type 2 diabetes in a managed care organization","volume":"2","author":"Keong","year":"2023","journal-title":"AJPM Focus."},{"issue":"1","key":"B29-20251006","doi-asserted-by":"crossref","first-page":"e001591","DOI":"10.1136\/bmjoq-2021-001591","article-title":"Improving annual albuminuria testing for individuals with diabetes","volume":"11","author":"Kam","year":"2022","journal-title":"BMJ Open Qual."},{"key":"B30-20251006","doi-asserted-by":"crossref","first-page":"893913","DOI":"10.1155\/2013\/893913","article-title":"Improving compliance with screening of diabetic patients for microalbuminuria in primary care practice","volume":"2013","author":"Anabtawi","year":"2013","journal-title":"ISRN Endocrinol."},{"issue":"11","key":"B31-20251006","doi-asserted-by":"crossref","first-page":"e110535","DOI":"10.1371\/journal.pone.0110535","article-title":"Primary care detection of chronic kidney disease in adults with Type-2 diabetes: the ADD-CKD study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease)","volume":"9","author":"Szczech","year":"2014","journal-title":"PLoS One."},{"issue":"8","key":"B32-20251006","doi-asserted-by":"crossref","first-page":"e0221325","DOI":"10.1371\/journal.pone.0221325","article-title":"Primary care physicians\u2019 perceptions of barriers and facilitators to management of chronic kidney disease: a mixed methods study","volume":"14","author":"Sperati","year":"2019","journal-title":"PLoS One."},{"issue":"7","key":"B33-20251006","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/dom.14684","article-title":"Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: barriers and solutions for improving uptake in routine clinical practice","volume":"24","author":"Khunti","year":"2022","journal-title":"Diabetes Obes Metab."},{"issue":"15","key":"B34-20251006","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2023.2854","article-title":"Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial","volume":"329","author":"Pagidipati","year":"2023","journal-title":"JAMA."},{"issue":"4","key":"B35-20251006","first-page":"e107","article-title":"Physician and patient tools to improve chronic kidney disease care","volume":"24","author":"Sequist","year":"2018","journal-title":"Am J Manag Care."},{"issue":"5","key":"B36-20251006","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.ajkd.2020.05.013","article-title":"Electronic decision support for management of CKD in primary care: a pragmatic randomized trial","volume":"76","author":"Peralta","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"13","key":"B37-20251006","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2311708","article-title":"Pragmatic trial of hospitalization rate in chronic kidney disease","volume":"390","author":"Vazquez","year":"2024","journal-title":"N Engl J Med."},{"issue":"1","key":"B38-20251006","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3122\/jabfm.19.1.54","article-title":"Primary care physicians\u2019 knowledge and practice patterns in the treatment of chronic kidney disease: an Upstate New York Practice-based Research Network (UNYNET) study","volume":"19","author":"Fox","year":"2006","journal-title":"J Am Board Fam Med."},{"issue":"1","key":"B39-20251006","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1186\/s12889-021-10959-7","article-title":"A qualitative study documenting unmet needs in the management of diabetic kidney disease (DKD) in the primary care setting","volume":"21","author":"Datar","year":"2021","journal-title":"BMC Public Health."},{"issue":"6","key":"B40-20251006","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1053\/j.ajkd.2011.08.028","article-title":"Automated clinical reminders for primary care providers in the care of CKD: a small cluster-randomized controlled trial","volume":"58","author":"Abdel-Kader","year":"2011","journal-title":"Am J Kidney Dis."},{"issue":"8","key":"B41-20251006","doi-asserted-by":"crossref","first-page":"100510","DOI":"10.1016\/j.xkme.2022.100510","article-title":"Hypoglycemia risk with SGLT2 inhibitors or glucagon-like peptide 1 receptor agonists versus sulfonylureas among medicare insured adults with CKD in the United States","volume":"4","author":"Zhao","year":"2022","journal-title":"Kidney Med."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:03:33Z","timestamp":1786478613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000000829","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"2024-09-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}